Disc Medicine, Inc. is facing a class action lawsuit after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. This announcement caused the company's stock to fall 22% on February 13, 2026. The Rosen Law Firm is investigating potential securities claims and preparing a class action to help investors recover losses without upfront fees. Investors who purchased Disc Medicine securities may be eligible to join the lawsuit for compensation.
Palantir (PLTR) is rated a buy due to its accelerating growth, expanding profit margins, and a strong business model. The company reported an impressive 85% year-over-year revenue growth and a 60% adjusted operating margin, outperforming many softwar...
Ethereum's price rose 3.09% to $1,794, showing potential for further gains toward $1,850-$1,900 if it holds above the $1,750 support level. Futures open interest increased, indicating growing market confidence, while on-chain data suggests deep accum...
Ki Young Ju, founder of CryptoQuant, predicts a possible Bitcoin rebound in the next few months but cautions that the bear market is not over. He explains that a rebound could be a temporary relief rather than a full recovery, as Bitcoin's price may ...
About one-third of Ethereum's consensus and execution nodes are located in the U.S., with a majority running the Lighthouse client, creating risks of finality stalls if U.S. infrastructure or policies disrupt these nodes. Finality requires two-thirds...
Standard Chartered maintains its Bitcoin price forecast of $100,000 by the end of 2026, attributing recent market declines to Strategy Inc.'s communication issues rather than Bitcoin's fundamentals. Strategy, the largest institutional Bitcoin holder ...
